Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Abstract

We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog, TCBA-TPQ, and conducted a pharmacokinetic study in laboratory rats. Our results indicated that the HPLC-MS/MS method was precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of TCBA-TPQ and plasma pharmacokinetics in rats. Our results provide a basis for future preclinical and clinical development of this promising anticancer marine analog.

• Authors: Jun-Xian Yu, Sukesh Voruganti, Dan-Dan Li, Jiang-Jiang Qin, Subhasree Nag, Su Xu, Sadanandan E Velu, Wei Wang, Ruiwen Zhang
• Journal: Chinese journal of natural medicines (Chin J Nat Med) Vol. 13 Issue 7 Pg. 554-60 (Jul 2015) ISSN: 1875-5364 [Electronic] China
• PMID: 26233847 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Validation Study)
• Copyright: Copyright © 2015 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Chemical References

• 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one
• Antineoplastic Agents
• Pyrroles
• Quinolones

Topics

• Animals
• Antineoplastic Agents (blood, pharmacokinetics)
• Chromatography, High Pressure Liquid (methods)
• Pyrroles (blood, pharmacokinetics)
• Quinolones (blood, pharmacokinetics)
• Rats, Sprague-Dawley
• Tandem Mass Spectrometry (methods)